Skip to main content
70°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Applied Therapeutics Inc
(NQ:
APLT
)
5.770
+0.170 (+3.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Applied Therapeutics Inc
< Previous
1
2
Next >
Applied Therapeutics Reports Second Quarter 2024 Financial Results
August 07, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Added to Russell 3000® Index
July 01, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Reports First Quarter 2024 Financial Results
May 09, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Inc. (NASDAQ: APLT) Leading the Way in Tuesday Trading Based on Percentage Gain
September 19, 2023
Via
Investor Brand Network
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
April 15, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
April 04, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
March 28, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
March 06, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Inc. (NASDAQ: APLT) Records 52-Week High Wednesday Morning
February 28, 2024
Via
Investor Brand Network
Applied Therapeutics Announces $100 Million Private Placement
February 28, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
February 28, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
February 15, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
January 04, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia
January 03, 2024
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics to Present at the UBS Biopharma Conference 2023
November 02, 2023
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7
November 01, 2023
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting
September 28, 2023
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023
September 06, 2023
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Reports Second Quarter 2023 Financial Results
August 10, 2023
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Provides Regulatory Update on Galactosemia Program
July 25, 2023
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association
June 22, 2023
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics to Present Data on AT-007 (Govorestat) Treatment in SORD Deficiency at the 2023 Annual Meeting of the Peripheral Nerve Society
June 15, 2023
From
Applied Therapeutics
Via
GlobeNewswire
Govorestat (AT-007) Receives Orphan Medicinal Product Designation from the EMA for Treatment of SORD Deficiency
May 25, 2023
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Reports First Quarter 2023 Financial Results
May 11, 2023
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission
April 24, 2023
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity
April 24, 2023
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results
March 23, 2023
From
Applied Therapeutics
Via
GlobeNewswire
Applied Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
Applied Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.